Key result
Target-specific sdAbs reverse Factor Xa inhibitor anticoagulation and normalize clot formation in patient samples.
Why the study?
Do target-specific single-domain antibodies (sdAbs) reverse Factor Xa inhibitor-induced anticoagulant effects in plasma and whole-blood samples from FXai-treated patients and controls?
Do target-specific single-domain antibodies (sdAbs) reverse Factor Xa inhibitor-induced anticoagulant effects in plasma and whole-blood samples from FXai-treated patients and controls?
Answers are grounded in this paper and cite their sources.
Target-specific single-domain antibodies effectively normalize Factor Xa inhibitor anticoagulant effects in vitro across various assays, offering a potential personalized reversal strategy and diagnostic tool.
edoxaban (n = 4) or rivaroxaban (n = 7).Dose-dependent effects of FXai ± sdAbs (or andexanet alfa) were assessed in plasma/blood samples from patients and controls using tissue factor-induced (i) diluted prothrombin time (dPT, 10 pM); (ii) ATP release (1 pM); (iii) thrombin generation (5 pM); (iv) clot turbidity (1/5 pM), and (v) a novel microfluidic perfusion assay (+ collagen, 1000 s -1 , 37°C).Plasma fibrinogen and FXai were quantified, as appropriate. ResultsIn control plasmas, individual sdAbs dose-dependently reversed FXai-induced inhibition of dPT and platelet ATP release.Under whole-blood flow, sdAbs neutralized FXai inhibitory effects on onset (40-129%, P<0.01) and extent of fibrin clot formation (64-96%, P<0.05).Andexanet-alfa and sdAbs were comparatively effective.In plasmas from apixaban-treated patients the α-Api sdAb normalized thrombin generation and clot turbidity (P<0.001) to baseline values.Clot turbidity changes correlated with the patients' high fibrinogen levels.Assessing all FXai-treated patients (levels 181-1148 nM) respective sdAbs corrected dPT (P<0.05) and improved fibrin formation under flow (P<0.01).Collectively, the new target-specific sdAbs effectively normalized anticoagulant FXai effects in almost all patient samples.Reversal was consistent for all various assays, irrespective of the type and level of the FXai. ConclusionsThe sdAb approach offers a promising personalized therapeutic strategy to reverse FXai-associated bleeding complications and provides a diagnostic tool for the reliable assessment of physiological coagulation potential in FXai-treated patients.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied Factor Xa inhibitor-induced anticoagulation / bleeding complications. Target-specific single-domain antibodies (sdAbs) vs. Andexanet alfa or untreated control was evaluated on Reversal of Factor Xa inhibitor effects on diluted prothrombin time, ATP release, thrombin generation, clot turbidity, and fibrin clot formation under flow (p=<0.001). Target-specific sdAbs normalized FXa inhibitor effects in patient samples, correcting diluted PT, thrombin generation and clot turbidity, and fibrin formation under flow.
Synapse has enriched 10 related papers. Consider them for comparative context: